Pokorney, S. D., Shrader, P., Thomas, L., Fonarow, G. C., Kowey, P. R., Singer, D. E., … Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators, . (2016). Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation, 134(15), 1122–1124. https://doi.org/10.1161/CIRCULATIONAHA.116.024333

Pokorney, Sean D., Peter Shrader, Laine Thomas, Gregg C. Fonarow, Peter R. Kowey, Daniel E. Singer, Jack Ansell, et al. “Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling.” Circulation 134, no. 15 (October 11, 2016): 1122–24. https://doi.org/10.1161/CIRCULATIONAHA.116.024333.

Pokorney SD, Shrader P, Thomas L, Fonarow GC, Kowey PR, Singer DE, et al. Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation. 2016 Oct 11;134(15):1122–4.

Pokorney, Sean D., et al. “Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling.” Circulation, vol. 134, no. 15, Oct. 2016, pp. 1122–24. Pubmed, doi:10.1161/CIRCULATIONAHA.116.024333.

Pokorney SD, Shrader P, Thomas L, Fonarow GC, Kowey PR, Singer DE, Ansell J, Gersh BJ, Mahaffey KW, Hylek EM, Go AS, Piccini JP, Peterson ED, Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators. Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation. 2016 Oct 11;134(15):1122–1124.